Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma
The incidence of cutaneous melanoma, a highly malignant skin cancer, is increasing yearly. While surgical removal of the tumor is the mainstay of treatment for patients with locally confined disease, those with metastases face uncertainty when it comes to their treatment. As melanoma is a relatively...
Main Authors: | Dejan Vidovic, Carman Giacomantonio |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/5/1321 |
Similar Items
-
Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG
by: Dejan Vidovic, et al.
Published: (2023-04-01) -
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
by: Pier Francesco Ferrucci, et al.
Published: (2021-03-01) -
Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress
by: Danielle K. DePalo, et al.
Published: (2023-02-01) -
Intratumoral therapies and in-situ vaccination for melanoma
by: Laura A. Huppert, et al.
Published: (2022-05-01) -
Cutaneous Breast Cancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 and Imiquimod: A Case Report and Brief Literature Review
by: Ashley Drohan, et al.
Published: (2022-05-01)